### **Alphaviruses**

**Current Biology** 

Edited by

Suresh Mahalingam

Lara J. Herrero

Institute for Glycomics Griffith University Gold Coast, QLD Australia

and

Belinda L. Herring

School of Biomedical Sciences, Faculty of Health Queensland University of Technology Brisbane, QLD Australia

### caister.com/alpha

Copyright © 2016

Caister Academic Press Norfolk, UK

www.caister.com

British Library Cataloguing-in-Publication Data A catalogue record for this book is available from the British Library

ISBN: 978-1-910190-15-9 (hardback) ISBN: 978-1-910190-16-6 (ebook)

Description or mention of instrumentation, software, or other products in this book does not imply endorsement by the author or publisher. The author and publisher do not assume responsibility for the validity of any products or procedures mentioned or described in this book or for the consequences of their use.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher. No claim to original U.S. Government works.

Cover images courtesy of Weiqiang Chen: chikungunya virus infection of bone cells in murine proximal tibial epiphysis.

### **Ebooks**

Ebooks supplied to individuals are single-user only and must not be reproduced, copied, stored in a retrieval system, or distributed by any means, electronic, mechanical, photocopying, email, internet or otherwise.

Ebooks supplied to academic libraries, corporations, government organizations, public libraries, and school libraries are subject to the terms and conditions specified by the supplier.

## Contents

	Contributors Preface	V
	Fieldce	ix
1	Alphavirus Genome Structure and Replication  Belinda L. Herring, Lara J. Herrero, Weiqiang Chen, Kuo-Ching Sheng,  Nestor E. Rulli and Suresh Mahalingam	1
2	Alphavirus Evolution  Lark L. Coffey, Scott C. Weaver and Naomi L. Forrester	21
3	Laboratory Diagnosis and Detection of Alphaviruses Linda Hueston	37
4	The Interaction of Alphaviruses with the Interferon System William B. Klimstra and Kate D. Ryman	49
5	Alphaviruses and their Role in Elucidating Antiviral Responses in Mosquitoes Melanie McFarlane and Alain Kohl	77
6	Animal Models of Alphavirus-induced Inflammatory Disease Lara J. Herrero, Adam Taylor, Pierre Roques, Brett A. Lidbury and Suresh Mahalingam	89
7	Clinical Manifestations of Arthritogenic Alphaviruses  Lara J. Herrero, Adam Taylor, Suan Sin Foo, Lynden Roberts,  Natkunam Ketheesan and Suresh Mahalingam	125
8	Encephalitic Alphaviruses  Clive S. McKimmie and John K. Fazakerley	139
9	Application of Alphavirus Vectors for Gene Therapy Kenneth Lundstrom	157
10	Case Study: Chikungunya Virus Lisa F.P. Ng	169
	Index	181

## Preface

Alphaviruses are small, enveloped, single-stranded positive-sense RNA viruses that are typically transmitted by arthropods, especially mosquitoes. A number of alphaviruses are known as clinically important human pathogens (e.g. Venezuelan equine encephalitis virus, chikungunya virus). Key areas of alphavirus research are focused on treatment and prevention of disease, but there is also considerable potential for harnessing alphaviruses as vaccine vectors and in gene therapy (e.g. Semliki Forest virus). In addition, alphaviruses have also been very valuable model systems for a wide range of basic studies in diverse areas such as cell biology, virology and immunology.

The book presents the current status of alphavirus research across a wide range of disciplines, but has a particular focus on molecular biology, pathogenesis and host interactions. The book, which is the first of its kind to focus specifically on alphaviruses, has been written in response to a

clear need within the alphavirus research community for a comprehensive and up-to-date overview of the field.

Each chapter has been written by leaders in that particular research field. Chapter topics covered include genome structure and replication; viral evolution; laboratory diagnosis and detection; interaction with the interferon system; antiviral responses in mosquitoes; animal models of alphavirus-induced inflammatory disease; clinical manifestations of arthritogenic alphaviruses; encephalitic alphaviruses; the application of alphavirus vectors for gene therapy; and chikungunya virus pathogenesis and the development of control strategies.

Finally, we thank all contributors for their hard work in providing chapters describing the latest developments in their fields of expertise and for their patience while waiting for the book to be published.

Professor Suresh Mahalingam

# Index

6K protein 5–6	c
A	Capsid protein 4–5, 8–13
	Chikungunya virus see CHIKV
ADE 66, 89	CHIKV 22-24, 27-28, 30, 31, 38, 52, 95-101, 110-113
Alphavirus assembly and egress 10–13	131–133, 140–141, 169–175
interactions between capsid and	clinical manifestations and pathology 131–133,
glycoproteins 12–13	171–172
nucleocapsid processing and assembly 10	encephalitis 140–141
structural protein processing and assembly 11	epidemiology 170–171
transport of viral components 12	innate immunity and interferons 172
Alphavirus expression vectors 158–164	interferons 52
cancer gene therapy 160	molecular biology 170
cancer vaccines 160–161	mouse models 95–101
clinical trials 163–164	non-human primate models 110–113
CNS therapy 162–163	phylogeny 22–24
oncolytic vectors 162	role of antibodies 173
tumour targeting 162	role of T cells 173–174
Alphavirus genomic organization 1	therapeutic antibodies 175
Alphavirus replication 6–13	therapeutics 174
assembly and egress 10-13	vaccines 174–175
attachment and entry 6–8	Cholesterol, requirement in budding 13
replication 8–10	, 1
Alphavirus structure 1–6	D
non-structural region 2–4	DC-SIGN and L-SIGN 6, 65-66
structural region 4–6	Demyelinating disease 150–151
Animal models 89–115	Detection and diagnosis 37-44
avian models 115	cell culture 40
guinea pig and hamster models 114–115	complement fixation 44
horse models 114	ELISA 41, 44–45
mouse models 89–109	haemagglutination inhibition 43
non-human primate models 110–114	immunofluorescence 41,44
Antibodies 41, 42–45, 52, 66, 103, 104–105, 110, 143,	laboratory animals 38
149, 173–175	mosquito cell culture 39
Antibody-dependent enhancement see ADE	mosquito inoculation 38–39
Apoptosis	neutralization tests 42–43
encephalitis 145–146	PCR 41–42
in mosquitoes 84–85	vertebrate cell culture 39
1	virus isolation 38
В	virus isolation 50
BFV 22, 24, 128–130	E
clinical manifestations 128–130	Eastern equine encephalitis virus see EEEV
phylogeny 24	EEEV 24–25, 29–30, 51, 56–57, 65–66, 106–107,
B lymphocytes 52, 93, 149, 173–175	
Barmah Forest virus see BFV	113–115, 141, 143–144 encephalitis 141, 143–144
	encephantis 171, 175-177

### caister.com/alpha

guinea pig and hamster models 114–115 horse model 114 interferons 51, 56–57, 65–66 microevolution 29–30 mouse models 106–107 non-human primate models 113–114 phylogeny 24–25 Encephalitis 100–109, 140–151 age-related virulence 145 antibodies 149 CHIKV 100–101, 140–141 CNS pathology 146–147 dissemination to CNS 142–143 EEEV 107, 141	N NK cells 52, 93 Non-human primate models CHIKV 110–113 RRV 113 VEEV, WEEV and EEEV 113–114 Non-structural region 2 nsP1 2, 4, 8–9, 63 nsP2 2–4, 8–9, 63–65, 172 nsP3 2, 4, 8–9, 12, 84, 144 nsP4 4, 8–9  O
immune response 147–151	O'nyong-nyong virus 130
neural cellular targets 144	Р
neuroinvasion via blood-brain barrier 143 neuroinvasion via olfactory tract 143	Phylogeny of alphaviruses 21–26
neuronal cell death 145–146	arthralgic 22–24 encephalitic 24–26
SFV 101–105, 140	•
Sindbis virus 105, 140 VEEV 109, 141	R DIC I/MDAS 52 55 40 62
WEEV 107–108, 141–142	RIG-I/MDA5 53–55, 60, 62 RNA interference, in mosquitoes 78–82
Envelope glycoproteins 5	Ross River virus see RRV
Evolution, alphaviral 26–32	RRV 66, 89–95, 113, 128
I	ADE 66 clinical manifestations 128
IFN-inducible antiviral effectors 60–63	mouse model 89-95
cGAMP synthase 63 IFIT protein family 61	non-human primate model 113
ISG15 61	phylogeny 24
ISG20 61-62	S
PKR and eIF2α pathways 60–61 UNC93b1 62–63	Semliki Forest virus see SFV
viperin 62	SFV 51–52, 101–105, 133–134, 140, 144, 146, 162, 163–164
zinc finger antiviral protein 62	clinical manifestations 133–134
IMD 82–84 Interferons 49–66	clinical trials 163-164
antagonism by viruses 63–66	encephalitis 140, 144, 146
pathogenesis 49–52	gene therapy 160–161 interferons 51–52
induction by infection 52–59	mouse model 101–105
induction by infection, myeloid cells 56–57 induction by infection, non-myeloid cells 54–56	tumour targeting 162
induction of antiviral effectors 57–59	Sindbis virus see SINV SINV 25–26, 52, 105–106, 133, 140, 160–161, 162
J	clinical manifestations 133
JAK/STAT pathway 57–58, 65, 82–84, 172	encephalitis 140
	gene therapy 160–161 interferons 52
M	mouse model 105–106
Macrophages 56–57, 66, 91–94, 98, 112	phylogeny 25-26
Mayaro virus 24, 131 Mouse models	tumour targeting 162
CHIKV 95–101	Structural region 4
EEEV 106-107	Т
RRV 89–95 Semliki Forest virus 101–105	T lymphocytes 52, 93, 150
Sindbis virus 105–106	Toll-like receptors 53–54, 82–84, 148
VEEV 108–109	V
WEEV 107-108	VEEV 25, 31–32, 50, 56–57, 108–109, 113–114, 141, 143–144, 160–161, 163 clinical trials 163

### caister.com/alpha

encephalitis 141, 143–144
envelope gene mutations 31–32
gene therapy 160–161
horse model 114
interferons 50, 56–57
mouse models 108–109
non-human primate models 113–114
phylogeny 25
Venezuelan equine encephalitis virus see VEEV

#### W

WEEV 25, 51, 107–108, 113–115, 141–142
avian models 115
encephalitis 141–142
guinea pig and hamster models 114–115
horse models 114
interferons 51
mouse models 107–108
non-human primate models 113–114
phylogeny 25
Western equine encephalitis virus see WEEV